Skip to main content
. 2019 Oct 20;10(26):6475–6480. doi: 10.7150/jca.30472

Figure 1.

Figure 1

Clinical guidance on potential causes of hypoglycemia with some corresponding laboratory findings in cases of tumor-related hypoglycemia. Modified from 3, 4, 32, 37, 38. Shortcuts: OHA - oral hypoglycemic agents, I - insulin, C-P - C-peptide, DS - drug screen, IGF * - increased pro-IGF-II, free IGF-II, IGF-II/IGF-I ratio, IAS - Insulin Autoimmune Syndrome (“Hirata disease”), TAS - Tumor Autoimmune Syndrome, A - insulin antibody (presence of either anti-insulin antibodies [insulin autoimmune syndrome, Hirata disease] or anti-insulin receptor antibodies [type B insulin resistance]. If TAN antibodies are produced by the tumor, ↑ - increased, ↓ - decreased, + - present, - - absent, N - normal